Experience of recombinant interferon alpha-2b and antioxidants usage in patients with positive HPV screening results

Kim D.G.; Khaldin A.A.

doi:https://doi.org/10.17116/klinderma20212005166

Kim D.G.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology of the Moscow Healthcare Department

Khaldin A.A.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology, Department of Healthcare

Experience of recombinant interferon alpha-2b and antioxidants usage in patients with positive HPV screening results

Authors:

Kim D.G., Khaldin A.A.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2021;20(5): 66‑72

DOI: 10.17116/klinderma20212005166

Read: 2709 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kim DG, Khaldin AA. Experience of recombinant interferon alpha-2b and antioxidants usage in patients with positive HPV screening results. Russian Journal of Clinical Dermatology and Venereology. 2021;20(5):66‑72. (In Russ.)
https://doi.org/10.17116/klinderma20212005166

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the effectiveness of recombinant interferon alpha-2b and antioxidants (alpha-tocopherol acetate and ascorbic acid) rectal suppositories in patients with subclinical and latent forms of human papillomavirus infection.

MATERIAL AND METHODS

The study included 140 patients. The biological material of urethra served as the material for the molecular biological study in men and the vagina and cervical canal in women. Patients with positive results of screening tests for HPV in the absence of clinical manifestations received a therapy with recombinant interferon alfa-2b in combination with antioxidants.

RESULTS

The effectiveness of interferon therapy in studied patients was 92.8 and 91.6% for men and women, respectively. The treatment was not accompanied by the significant side effects.

CONCLUSION

The treatment of patients with positive HPV screening tests and no clinical manifestations with recombinant interferon alpha-2b and antioxidants in the form of rectal suppositories showed a good efficacy and safety profile. It reduced the progression of cellular changes associated with high oncogenic risk HPV infection into dysplasia and cancer as well as the likelihood of sexual transmission of infection since it contributed to the complete or partial elimination of HPV in a shortened period.

Keywords:

?sexually transmitted infections

anal-genital papillomavirus infection

human papillomavirus

interferon alpha-2b

Authors:

Kim D.G.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology of the Moscow Healthcare Department

Khaldin A.A.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology, Department of Healthcare

Received:

05.08.2021

Accepted:

26.08.2021

Close metadata

References:

World Health Organization: Human papillomavirus laboratory manual. First edition. 2009. Accessed Dec 02, 2020. https://www.who.int/immunization/hpv/learn/hpv_laboratory_manual__who_ivb_2009_2010.pdf
Bruni L, Diaz M, Castellsagueґ X, Ferrer E, Bosch FX, de Sanjoseґ S. Cervical human papillomavirusprevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202:1789-1799. PMID: 21067372. https://doi.org/10.1086/657321
Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, Steinau M, Watson M, Wilkinson EJ, Hopenhayn C, Copeland G, Cozen W, Peters ES, Huang Y, Saber MS, Altekruse S and Goodman MT; HPV Typing of Cancers Workgroup. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015; 107:djv086.
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.; WHO International Agency for Research on Cancer Monograph Working Group. A review of humancarcinogens — Part B: biological agents. Lancet Oncol. 2009;10(4):321-322.
Lopukhov PD. Nauchno-metodicheskoe obosnovanie napravlenii optimizatsiiepidemiologicheskogo nadzora i profilaktiki papillomavirusnoi infektsii. Dissertatsiya na soiskanie uchenoi stepeni kandidata meditsinskikh nauk. Moskva 2018 FGAOU vysshego obrazovaniya Pervyi Moskovskii Gosudarstvennyi Meditsinskii Universitet im. I.M. Sechenova. (In Russ.).
Kiviat N, Koutsky LA, Paavonen J. Sexually Transmitted Diseases. 3rd ed. Eds Holms K.K., et al. New York. 1999;811-831.
Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S.ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 17 June 2019
Ducatman BS The Impact and Burden of Human Papillomavirus—Associated Disease. Arch Pathol Lab Med. 2018;142(6):686-687. https://doi.org/10.5858/arpa.2018-0084-ED
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. PMID: 15761078. https://doi.org/10.3322/canjclin.55.2.74
Cobos C, Figueroa JA, Mirandola L, Colombo M, Summers G, et al. The role of human papilloma virus (HPV) infection in non-anogenitalcancer and the promise of immunotherapy: a review. Int Rev Immunol. 2014;33:383-401.
Glukhova YuK, Volchenko NN. Draft program of the national cytological screening of cervical cancer. Novosti klinicheskoi tsitologii Rossii. 2018;22(3-4):22-30. (In Russ.).
Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta_analysis. Am J Epidemiol. 2008;168(2):123-137.
Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, Wadell G. Humanpapillomavirus infection is transient in young women: A population-based cohort study. J Infect Dis. 1995;171(4):1026-1030.
Jaisamrarn U, Castellsague X, Garland SM, Naud P, Palmroth J, Del Rosario_Raymundo MR, Wheeler CM. Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study. PLoS One. 2013;8(12):e79260. https://doi.org/10.1371/annotation/cea59317-929c-464a-b3f7-e095248f229a
Amador_Molina A, Hernandez_Valencia JF, Lamoyi E, Contreras_Paredes A, Lizano M. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses. 2013;5(11):2624-26427.
Podzolkova NM, Rogovskaya SI, Fadeev IE, Damirov MM, Sozaeva LG, Osadchev VB. Papillomavirusnaya infektsiya v akusherstve i ginekologii: rukovodstvo dlya vrachei. M.: GEOTAR Media; 2012. (In Russ.).
Misson DR, Abdalla DR, Borges AM, Shimba DS, Adad SJ, Michelin MA, Murta EF. Cytokine serum levels in patients with cervical intraepithelial neoplasia grade II_III treated with intralesional interferon_α 2b. Tumori. 2011; 97(5):578-584.
Prilepskaya VN, Rogovskaya SI, Bebneva TN, Mezhevitinova EA, Petrunin DD. The use of interferon preparations in the treatment of low-grade squamous intraepithelial lesions of the cervix. AG info. 2008;3:15-21. (In Russ.).
Ershov FI. Sistema interferonov v norme i pripatologii. M.: Meditsina; 1998. (In Russ.).
Yang J, Pu YG, Zeng ZM, et al. Interferon for the treatment of genital warts: a systematic review. BMC Infect Dis. 2009;9:156.
Vasil’ev AN. Antioxidant impact on specific antiviral activity of human recombinant interferon α-2b with respect to herpes simplex in cell culture. Antibiotiki i khimioterapiya. 2010;55(7-8):21-25. (In Russ.).
Vasil’ev AN, Deryabin PG, Galegov GA. Antiviral activity of antioxidants and their combination with human recombinant interferon alpha-2b against the influenza A/H5N1 virus. Tsitokiny i vospalenie. 2011;10(2):27-32. (In Russ.).
Look MP, Gerard A, Rao GS, Sudhop T. Interferon/antioxidant combination therapy for chronic hepatitis C — a controlled pilot trial. Antivirul research. 1999;43:113-122.